Filing Flows › Organogenesis Holdings (ORGO) › Guidance & outlook
Organogenesis Holdings (ORGO) guidance and outlook
Organogenesis Holdings (ORGO) updated its guidance on Nov 5, 2026: Revenue +68% to +74% for Q4 2026. Organogenesis Holdings' 10-Q filed Nov 5, 2026 makes 13 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | Q4 2026 | +68% to +74% | new |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We have generated and intend to continue to generate data from clinical trials, real-world outcomes and health economics research that validate the clinical efficacy and value proposition offered by our products.
- Our product development expertise and multiple technology platforms provide a robust product pipeline, which we believe will drive future growth.
- Our Surgical & Sports Medicine products include NuShield and CYGNUS Matrix for surgical applications in targeted soft tissue repairs; and Affinity, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting.
- While we believe CMS’ finalized PFS and OPPS payment structure will curb abuse under the current system and the resulting rapid escalation in Medicare spending, and ensure a much-needed consistent payment approach across sites of care, the changes could also materially and adversely impact utilization of our products, our business, our revenue and our profitability.
- While the longer-term impact of CMS’ updated Medicare reimbursement changes is still uncertain, we experienced a significant year-over-year decline in revenue in the first three quarters of fiscal year 2026, and we will continue to experience a significant year-over-year decline in revenue in the fourth quarter of fiscal year 2026.
- We are preparing responses to the information requests and currently expect to complete the identified remediation work in the Norwood facility by September 30, 2027.
- We planned to transition our Dermagraft manufacturing to our newly-leased biomanufacturing facility in Smithfield, Rhode Island and to commence sales by the end of 2027, however, given the decline in the skin substitute market and the decline in our net revenue, we are delaying the relaunch of Dermagraft and cannot currently project specific timing.
- We expect to recognize grant income as we recognize the related expenses that the grant is intended to compensate .
- In determining whether a valuation allowance for deferred tax assets is necessary, we analyze both positive and negative evidence related to the realization of deferred tax assets including projected future taxable income, recent financial results and estimates of future reversals of deferred tax assets and liabilities.
- In addition, we consider whether it is more likely than not that a tax position will be sustained on examination by taxing authorities based on the technical merits of the position.
- The remaining capacity under the ATM Agreement is not committed financing and does not assure that we will be able to raise $73.2 million, or any specific amount, under the ATM Agreement.
- To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute on our business strategy, we anticipate that they will be obtained through additional equity or debt financings, other strategic transactions or a combination of these potential sources of funds.
Organogenesis Holdings' latest quarter
Organogenesis Holdings, Q3 2026: revenue $45.5M (-70% year over year), operating margin -64.9%, net loss $29.6M, operating cash flow −$18.6M. The chart follows the revenue to costs, profit and cash.
Questions
Did Organogenesis Holdings raise or lower its guidance?
Organogenesis Holdings (ORGO) updated its guidance on Nov 5, 2026: Revenue +68% to +74% for Q4 2026.
What does Organogenesis Holdings expect?
We have generated and intend to continue to generate data from clinical trials, real-world outcomes and health economics research that validate the clinical efficacy and value proposition offered by our products. Our product development expertise and multiple technology platforms provide a robust product pipeline, which we believe will drive future growth. Our Surgical & Sports Medicine products include NuShield and CYGNUS Matrix for surgical applications in targeted soft tissue repairs; and Affinity, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.